Stay updated on Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial page.

Latest updates to the Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe site footer revision label changes from v3.7.2 to v3.8.0.SummaryDifference0.1%

- Check22 days agoChange DetectedAn NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the clinical trial record.SummaryDifference0.4%

- Check29 days agoChange DetectedThe site footer now displays revision v3.7.2 instead of v3.7.1.SummaryDifference0.1%

- Check36 days agoChange DetectedThe site footer revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check57 days agoChange DetectedRevision label on the page updated from v3.6.6 to v3.7.0. This reflects an update to the page's revision-tracking UI/template, not a modification to the study data or history entries.SummaryDifference0.1%

- Check78 days agoChange DetectedThe page shows a revision bump from v3.6.5 to v3.6.6, indicating a backend or UI update; the study history content remains unchanged.SummaryDifference0.1%

Stay in the know with updates to Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab & Tremelumab vs SoC in NSCLC Clinical Trial page.